The HealthCare unit of Bayer (BAYRY) and its partner,  Johnson & Johnson’s (NYSE:JNJ) Janssen Research and Development unit, received some disappointing news recently when an advisory panel of the U.S. Food and Drug Administration (FDA) recommended against approving their blood thinner Xarelto for an additional indication.
The partners are looking to get Xarelto approved for the reduction of the risk of secondary cardiovascular events in patients suffering from acute coronary syndrome … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards